KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $62.4 million.

  • Jazz Pharmaceuticals' Change in Account Payables rose 587.55% to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.7 million, marking a year-over-year increase of 362.33%. This contributed to the annual value of -$20.1 million for FY2024, which is 309.03% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Change in Account Payables is $62.4 million, which was up 592.33% from -$12.7 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Change in Account Payables high stood at $62.4 million for Q3 2025, and its period low was -$32.0 million during Q2 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Change in Account Payables had a median value of -$3.1 million in 2024 and averaged $5.3 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Change in Account Payables spiked by 20,493.66% in 2022, and later tumbled by 1,042.52% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Change in Account Payables stood at $37.9 million in 2021, then tumbled by 140.72% to -$15.4 million in 2022, then skyrocketed by 47.43% to -$8.1 million in 2023, then surged by 61.31% to -$3.1 million in 2024, then skyrocketed by 587.55% to $62.4 million in 2025.
  • Its Change in Account Payables stands at $62.4 million for Q3 2025, versus -$12.7 million for Q2 2025 and $19.1 million for Q1 2025.